2022
Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies.
Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.Peer-Reviewed Original ResearchMRI-ultrasound fusion biopsyNCCN risk classificationMRI-ultrasound fusionFusion biopsyLower riskActive surveillanceNCCN riskSystematic biopsyCore biopsyRisk classificationFirst-time biopsyInitial active surveillanceProportion of patientsMajority of patientsEra of MRIPrimary study objectiveProstate cancer risk classificationNCCN definitionsMedian PSASurveillance biopsiesBiopsy cohortRetrospective studySingle institutionProstate cancerBiopsy
2021
Doubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy
Ghabili K, Paulson N, Syed JS, Nawaf CB, Khajir G, Martin DT, Onofrey J, Leapman MS, Levi A, Weinreb JC, Humphrey PA, Sprenkle PC. Doubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy. Case Reports In Urology 2021, 2021: 2687416. PMID: 33936831, PMCID: PMC8054861, DOI: 10.1155/2021/2687416.Peer-Reviewed Original ResearchBiopsy scoreRadical prostatectomyActive surveillanceBiopsy Gleason grade groupGleason grade group 2Gleason grade group 4Low-risk prostate cancerActive surveillance populationGrade group 4Subsequent surveillance biopsiesOrgan-confined diseaseGrade group 2Gleason grade groupLow-risk categoryBiopsy reclassificationDisease reclassificationSurveillance biopsiesFinal pathologyThird biopsySecond biopsySurveillance populationProstate cancerAdverse featuresGroup 2Genomic score
2016
MRI-US fusion targeted biopsy results in men with a history of prior cancer.
Nawaf C, Rosoff J, Lu A, Weinreb J, Humphrey P, Levi A, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in men with a history of prior cancer. Journal Of Clinical Oncology 2016, 34: 88-88. DOI: 10.1200/jco.2016.34.2_suppl.88.Peer-Reviewed Original ResearchMRI-US fusionGleason scoreActive surveillanceFusion biopsySignificant cancerProstate cancerGleason 6 prostate cancerPre-biopsy mpMRIPrevious prostate biopsyAppropriate risk stratificationMRI-ultrasound fusionBiopsy of lesionsMaximum Gleason scoreUpstaging rateC cancerPrior cancerPrior biopsyMapping biopsyRisk stratificationHigher PSABiopsy resultsProstate biopsyInclusion criteriaMp-MRIPatient basisProstate cancer detection rates of negative MP-MRIs.
Lu A, Nawaf C, Weinreb J, Rosoff J, Schulam P, Humphrey P, Levi A, Sprenkle P. Prostate cancer detection rates of negative MP-MRIs. Journal Of Clinical Oncology 2016, 34: 91-91. DOI: 10.1200/jco.2016.34.2_suppl.91.Peer-Reviewed Original ResearchTemplate mapping biopsyNegative predictive valueNegative MRIMapping biopsyActive surveillanceSignificant cancerProstate cancer detection rateSignificant CaPMRI-US fusion biopsyHigh negative predictive valueBiopsy-naive menPrior negative biopsyBiopsy-naïve patientsCancer detection rateProstate cancer detectionDiffusion-weighted imagingDynamic contrast enhancementNIH National InstituteNaïve patientsNegative menGleason 7High suspicionNegative biopsyPatient counselingGleason 4